Lixudebart (ALE.F02) is a first-in-class monoclonal antibody in clinical development for multi-organ fibrosis Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing
Sens, an Irish market research firm blending behavioural science with BehaviourTech and AI, appoints Mike Abel, a global advertising leader, as non-executive chairman.
Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.